(0)
The DTRA Chem Bio Technologies, Vaccines and Therapeutics Division forms industry partnership with Evrys Bio to accelerate treatment for alphavirus, arenavirus and filovirus infections
DOYLESTOWN, Pa., July 13, 2021 (GLOBE NEWSWIRE) Evrys Bio, a biotech company developing Next Gen Antivirals, was awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents. The proposed drug intends to improve disease survival after exposure to one or more viruses from three families: alphaviruses, arenaviruses and filoviruses. Evrys Bio s broad-spectrum antiviral technology is based on the discovery that certain human proteins, called sirtuins, normally defend the human (host) cell from being invaded by pathogens. The novel drug will target the human SIRT-2 protein.
Evrys Bio
Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses
Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses
The DTRA Chem Bio Technologies, Vaccines and Therapeutics Division forms industry partnership with Evrys Bio to accelerate treatment for alphavirus, arenavirus and filovirus infections
DOYLESTOWN, Pa., July 13, 2021 (GLOBE NEWSWIRE) Evrys Bio, a biotech company developing Next Gen Antivirals, was awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents. The proposed drug intends to improve disease survival after exposure to one or more viruses from three families: alphaviruses, arenaviruses and filoviruses. Evrys Bio’s broad-spectrum antiviral technology is based on the discovery that certain human proteins, called sirtuins, normal
Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses - Press Release wiredprnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wiredprnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective .
Evrys BioJuly 13, 2021 GMT
DOYLESTOWN, Pa., July 13, 2021 (GLOBE NEWSWIRE) Evrys Bio, a biotech company developing Next Gen Antivirals, was awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents. The proposed drug intends to improve disease survival after exposure to one or more viruses from three families: alphaviruses, arenaviruses and filoviruses. Evrys Bio’s broad-spectrum antiviral technology is based on the discovery that certain human proteins, called sirtuins, normally defend the human (host) cell from being invaded by pathogens. The novel drug will target the human SIRT-2 protein.
Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses
The DTRA Chem Bio Technologies, Vaccines and Therapeutics Division forms industry partnership with Evrys Bio to accelerate treatment for alphavirus, arenavirus and filovirus infections
July 13, 2021 00:04 ET | Source: Evrys Bio Evrys Bio Doylestown, Pennsylvania, UNITED STATES
DOYLESTOWN, Pa., July 13, 2021 (GLOBE NEWSWIRE) Evrys Bio, a biotech company developing Next Gen Antivirals, was awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents. The proposed drug intends to improve disease survival after exposure to one or more viruses from three families: alphaviruses, arenaviruses and filoviruses. Evrys Bio’s broad-spectrum antiviral technology is based on the discovery that certain human proteins, called sir